Innovative Screening Method for Barrett’s Esophagus

Potential Impact on Esophageal Cancer Outcomes

A groundbreaking screening technique utilizing a sponge-on-a-string device may enhance the detection of Barrett’s esophagus, a significant precursor to esophageal cancer. Esophageal cancer ranks as the eighth most prevalent cancer and the sixth leading cause of cancer-related mortality. Barrett’s esophagus (BE) involves the replacement of normal esophageal lining with abnormal cells, which can progress to cancer. While the likelihood of developing esophageal cancer from BE is relatively low, ongoing monitoring is crucial, as better outcomes are observed in patients who eventually develop the disease.

Limitations of Current Screening Methods

Traditional screening approaches primarily target patients with acid reflux disease but have been found ineffective in identifying Barrett’s esophagus. Research indicates that merely one-third of individuals diagnosed with BE report a history of acid reflux, highlighting a significant gap in current screening strategies. Consequently, the exploration of new screening techniques has become essential. Researchers from the USA and China have investigated the safety, feasibility, and effectiveness of the EsophaCap device, sharing their findings in the journal Clinical Cancer Research.

Overview of the EsophaCap Device

Mechanism of Action

The EsophaCap is a swallowable capsule sponge device that is connected to a string, designed to collect cellular samples from the esophagus. Upon swallowing the capsule, the string remains outside the mouth. Once in the stomach, the capsule dissolves, releasing a sponge that expands to gather cells from the esophagus as it is withdrawn from the body.

Study Findings

In a study involving 80 participants, 85% of the subjects successfully swallowed the EsophaCap, with 100% retrieval of the sponge. No adverse effects were reported among any of the participants. The collected cell samples were then analyzed using a methylation on beads (MOB) technique, which allows for DNA analysis from small samples. The study examined eight genes associated with Barrett’s esophagus, comparing samples from diagnosed patients with those from control individuals. The EsophaCap not only proved safe and effective in cell retrieval but also demonstrated that the MOB technique was more sensitive than conventional DNA extraction methods, establishing a reliable diagnostic method.

Advantages of the EsophaCap Screening Method

Cost-Effectiveness and Minimally Invasive Nature

Current endoscopic screening procedures are often costly and not reliably effective for detecting Barrett’s esophagus. The EsophaCap presents a promising alternative, being simple to use, safe, cost-effective, and minimally invasive for collecting esophageal cell samples. When combined with the methylation on beads DNA analysis, this method could significantly enhance screening efforts for Barrett’s esophagus and ultimately improve outcomes for esophageal cancer patients. The encouraging results from this study underscore the necessity for further research involving larger populations.

References

Wang, Z., Kambhampati, S., Cheng, Y., Ma, K., Simsek, C., Tieu, A. H., . . . Meltzer, S. J. (2019). Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett’s Esophagus: A Prospective Validation Study. Clinical Cancer Research. doi:10.1158/1078-0432.ccr-18-3696
Smith, P. (2019, January 22). Test for esophageal cancer could save millions of lives. Retrieved February 2, 2019, from https://www.eurekalert.org/pub_releases/2019-01/jhm-tfe012219.php
Image source: https://www.eurekalert.org/multimedia/pub/190842.php?from=418185